NEW YORK and BERLIN, June 26, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental...
ELE-101 is a patent-protected, synthetic formulation of psilocin, designed to offer the therapeutic benefits of psilocybin in a more consistent, controllable, and shorter treatment paradigm of...
NEW YORK and BERLIN, May 31, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (atai or Company), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental...
NEW YORK and BERLIN, May 23, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (atai or Company), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental...
First participant dosed in Phase 1b trial of VLS-01 with data expected in 2H™24; Phase 2 study in TRD patients anticipated to initiate around YE™24Beckley Psytech's Phase 2a study of BPL-003 in TRD...
The BPL-003 Phase 2a trial is an open-label study investigating BPL-003 as both monotherapy and adjunctive to SSRIs in patients with Treatment Resistant Depression.Initial results from the recently...
BPL-003 is Beckley Psytech's novel patent-protected benzoate salt formulation of 5-MeO-DMT that is administered intranasally.BPL-003 was shown to be safe and well-tolerated with a predictable...
Strategic investment in Beckley Psytech to accelerate the development of psychedelic-based therapies that fit within the two hour in-clinic treatment paradigm established by Spravato®Initial BPL-003...
- A single dose of BPL-003 demonstrated a rapid and durable antidepressant effect in TRD patients, with 45% of patients in clinical remission at week 12 - 55% of patients achieved a clinical response...
IntelGenx Enters Into a Third Amended Agreement atai Life Sciences